Cargando…
Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS–p110 crosstalk
Compensatory mechanisms, such as relief of AKT-ErbB3-negative feedback, are known to desensitize ErbB2-dependent tumours to targeted therapy. Here we describe an adaptation mechanism leading to reactivation of the PI3K/AKT pathway during trastuzumab treatment, which occurs independently of ErbB3 re-...
Autores principales: | Tamaskovic, Rastislav, Schwill, Martin, Nagy-Davidescu, Gabriela, Jost, Christian, Schaefer, Dagmar C., Verdurmen, Wouter P. R., Schaefer, Jonas V., Honegger, Annemarie, Plückthun, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895728/ https://www.ncbi.nlm.nih.gov/pubmed/27255951 http://dx.doi.org/10.1038/ncomms11672 |
Ejemplares similares
-
Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
por: Kast, Florian, et al.
Publicado: (2021) -
Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014) -
Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma
por: Goldshmit, Yona, et al.
Publicado: (2014) -
Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011) -
Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)